Verrica Pharmaceuticals Inc.   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: West Chester PA United States (2013)

Organization Overview

First Clinical Trial
2017
NCT03186378
First Marketed Drug
2023
cantharidin (Ycanth)
First NDA Approval
2023
cantharidin (Ycanth)
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Verrica Pharmaceuticals Inc. | VERRICA PHARMS